What is it about?
In this issue of Alzheimer’s & Dementia, the results from the “Comparative analytical performance of multiple plasma Aβ42and Aβ40 assays and their ability to predict positron emission tomography amyloid positivity” represent the collaborative work supported by the Foundation for the National Institutes of Health (FNIH) and 11 partner organizations from across the public and private sectors. The study conducted a unique large-scale comparative assessment of blood tests that measure the levels of amyloid beta in blood with all data made available to any interested parties. The study employed samples from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) and confirmed that blood tests can predict patients’ amyloid positivity, which is important for Alzheimer’s diagnosis
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
. The blood-based tests will serve as a powerful, cost-effective, and readily available tool to identify individuals to participate in clinical trials and will accelerate the development of effective treatments for Alzheimer’s disease.
Perspectives
Project data and methodology report are publicly available on the ADNI Laboratory of Neuroimaging (LONI) website: https://ida.loni.usc.edu/login.jsp To learn more about the Plasma Aβ Project, visit https://fnih.org/our-programs/biomarkers-consortium/programs/plasma-abeta
Stephen Zicha
Takeda Pharmaceutical Company Ltd.
Read the Original
This page is a summary of: Comparative analytical performance of multiple plasma Aβ42 and Aβ40 assays and their ability to predict positron emission tomography amyloid positivity, Alzheimer s & Dementia, July 2022, Wiley,
DOI: 10.1002/alz.12697.
You can read the full text:
Resources
Contributors
The following have contributed to this page
